CharactHer: A Study of the Molecular and Cytogenetic Characteristics of HER2-positive Breast Cancers to Predict Durable Complete Response After Chemotherapy and Trastuzumab
Type of Study: Translational
This is a pilot retrospective laboratory-based cohort study.
Eligible patients will be identified at each one of the participating institutions by a
systematic cross-matching of the datasets of Medical Oncology, Pathology and Pharmacy
Cohort 1: TNM stage II-IV breast cancer patients with highly trastuzumab-sensitive tumours.
Cohort 2: (Control group) TNM stage II-IV breast cancer patients with trastuzumab-refractory
Observational Model: Cohort, Time Perspective: Retrospective
Panel of molecular and cytogenetic biomarkers able to predict Durable Complete Response (DCR) after chemotherapy and trastuzumab in patients with HER2-positive locally advanced or metastatic breast cancer.
Giuseppe Gullo, Medicine and Surgery
St. Vincent's University Hospital
Ireland: Health Information and Quality Authority